AstraZeneca Goes All In On AL Amyloidosis With Caelum Acquisition
Deal Could Be Worth Up To $500m
AstraZeneca’s recently-acquired Alexion unit is paying $150m upfront to buy the remainder of Caelum Biosciences and its late-stage therapy for light chain amyloidosis, a rare disease in which misfolded amyloid proteins build up in organs throughout the body, including the heart and kidneys.
